October 19, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

SymBio Engages MTS Health Partners to Accelerate Strategic Partnership Activities Primarily in Europe in Preparation for the Commercialization of Brincidofovir (BCV)

Tokyo, Japan, October 19, 2026 – SymBio Pharmaceuticals Limited ("SymBio" or the "Company") today announced that it has engaged MTS Health Partners (Headquarters: New York) as an advisor and initiated the selection of strategic partners for the commercialization of brincidofovir ("BCV"), with a focus on Europe where early approval of BCV targeting adenovirus infection following hematopoietic stem cell transplantation is anticipated.

Statement from Fuminori Yoshida, President and CEO: "We will establish a stable supply system in preparation for the new drug approval of BCV in the UK and Europe. To achieve this, we will move quickly to form partnerships with strong companies equipped with supply networks for intractable and rare diseases, enabling us to deliver an effective and safe drug as soon as possible."

The Company does not expect this matter to have a material impact on its consolidated financial results for the fiscal year ending December 2026.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125

Notes

About MTS Health Partners

MTS Health Partners is a leading investment bank that provides aligned strategic and financial advisory services to healthcare companies of all sizes. From global corporations to venture-backed startups, MTS delivers expert advice on M&A, capital raising, and strategic restructuring within the life sciences and healthcare services sectors.

About SymBio Pharmaceuticals: BCV Business Strategy Centered on Three Therapeutic Areas

Since obtaining the global license for brincidofovir ("BCV") in September 2019, SymBio Pharmaceuticals has conducted joint research with world-leading research institutions in three therapeutic areas—double-stranded DNA virus infections, solid tumors, and neurodegenerative diseases—with the aim of unlocking BCV's potential in each area. SymBio is concentrating its management resources on the development of BCV, primarily for adenovirus infection following hematopoietic stem cell transplantation, progressive multifocal leukoencephalopathy ("PML"), glioblastoma, head and neck cancer, and EBV-associated gastric cancer. Through global business development, SymBio aims to maximize the business value of BCV.